Humanin Protocol: Complete Cycling & Dosing Guide

Humanin Protocol: Complete Cycling & Dosing Guide

Overview

Humanin is a 21-amino acid mitochondrial-derived peptide (MDP) that functions as a cellular survival factor, primarily through activation of the JAK2/STAT3 and PI3K/Akt signaling pathways. It operates both extracellularly via receptor binding (CNTFR/WSX-1/gp130 complex) and intracellularly by blocking pro-apoptotic proteins like BAX, making it a dual-action neuroprotective and metabolic agent.

The compound shows particular promise for metabolic health, mitochondrial function, insulin sensitivity, and age-related decline—areas where circulating humanin levels naturally decrease. Unlike most peptides, humanin maintains a relatively favorable safety profile in preclinical work, though long-term human data remains limited due to its research-only status.

Humanin is available exclusively as a research peptide. It is not approved by any regulatory body and quality/purity depends entirely on vendor reliability. This protocol assumes pharmaceutical-grade material from a vetted source.

Standard Protocol

Injectable Protocol (Most Common)

• Dose Range: 100–500 mcg per injection
• Frequency: Once daily or 3 times per week
• Typical Starting Dose: 200 mcg, 3x per week
• Route: Subcutaneous injection (intramuscular possible but less common)
• Cycle Length: 12–16 weeks on, 4–8 weeks off
• Administration Time: Morning, ideally 30–60 minutes before food

Intranasal Protocol (Alternative)

• Dose Range: 200–400 mcg once daily
• Delivery: Nasal spray or powder insufflation
• Cycle Length: 12–16 weeks on, 4–8 weeks off
• Bioavailability: Lower than injection; less studied in humans

The injectable protocol is more predictable and produces more consistent blood levels. Most experienced users favor subcutaneous administration in the abdomen or thigh for convenience and reduced site irritation compared to intramuscular routes.

Goal-Specific Protocols

Protocol A: Metabolic Health & Fat Loss

Evidence Tier: 2 (animal models show visceral fat reduction and improved insulin sensitivity)

• Dose: 200 mcg, once daily (7 days/week) or 300 mcg, 3x per week
• Cycle: 16 weeks on, 6 weeks off
• Stack Option: Combine with GLP-1 agonist (semaglutide/tirzepatide) for synergistic insulin sensitivity
• Monitoring: Track fasting glucose, insulin levels, body composition (especially visceral fat via DEXA or ultrasound)
• Expectation: Measurable insulin sensitivity improvement by week 6–8; fat loss acceleration by week 10–12, primarily visceral

Protocol B: Mitochondrial Function & Energy

Evidence Tier: 2 (autophagy induction and muscle mitochondrial density in animals)

• Dose: 250–400 mcg, once daily
• Cycle: 14 weeks on, 6 weeks off
• Timing: Inject 60 minutes before high-intensity training
• Stack Option: NAD+ booster (NMN 500 mg daily) or CoQ10 (300 mg daily) to amplify mitochondrial benefits
• Monitoring: Subjective energy/fatigue rating; VO2max testing at weeks 0, 8, and 14
• Expectation: Improved training recovery by week 3–4; sustained energy increase by week 8; athletic performance gains variable

Protocol C: Neuroprotection & Cognitive Health

Evidence Tier: 3 (observational human data; no RCTs with validated cognitive endpoints)

• Dose: 300 mcg, once daily
• Cycle: 16 weeks on, 4 weeks off, repeat
• Frequency: Daily dosing more important than pulsed frequency for CNS effects
• Stack Option: Alpha-GPC (600 mg daily), Lion's Mane (2 g daily), or Lithium orotate (5 mg daily)
• Monitoring: Cognitive battery (NIH Toolbox or similar) at baseline, week 8, week 16
• Expectation: Subjective clarity by week 2–3; measurable cognitive improvements (if any) emerge by week 10–12

Protocol D: Injury Recovery & Tissue Protection

Evidence Tier: 2 (neuronal and mitochondrial protection in animal models)

• Dose: 300–400 mcg, once daily during acute injury phase
• Acute Phase Duration: Start immediately post-injury; continue for 8 weeks
• Transition: Drop to maintenance (200 mcg, 3x/week) for weeks 9–16
• Stack Option: Combine with BPC-157 (250 mcg daily) and TB-500 (2 mg weekly) for multi-pathway protection
• Monitoring: Pain/mobility scales; inflammation markers (CRP, ESR) weekly
• Expectation: Reduced neurological deficits by week 2–3 (animal data); subjective pain reduction 4–6 weeks; tissue repair acceleration weeks 6–12

Protocol E: Anti-Inflammatory & Immune Support

Evidence Tier: 2 (animal models; one human RCT combining exercise + astaxanthin)

• Dose: 250 mcg, once daily
• Cycle: 12 weeks on, 4 weeks off
• Stack Option: Combine with exercise (resistance or endurance training increases humanin levels naturally); astaxanthin 12 mg daily
• Monitoring: Inflammatory markers (TNF-α, IL-6, hsCRP) at baseline, week 6, week 12
• Expectation: Baseline inflammatory elevation week 1–2 (potential cytokine release); improvement in inflammatory markers by week 6–8

Protocol F: Cardiovascular Health & Longevity

Evidence Tier: 3 (observational: lower humanin associated with MI/angina; no RCT proof)

• Dose: 250 mcg, once daily
• Cycle: 16 weeks on, 8 weeks off (longer cycle for sustained effect)
• Stack Option: Combine with standard cardiovascular agents (statins, ACE inhibitors); add CoQ10 (300 mg daily)
• Monitoring: Lipid panel, inflammatory markers, endothelial function (flow-mediated dilation) quarterly
• Expectation: Improved endothelial markers by week 8; measurable improvements in lipid or inflammatory markers week 10–14

How to Administer Step-by-Step

Reconstitution (if lyophilized powder)

1. Determine total humanin content (typically 1–5 mg per vial)
2. Calculate desired concentration: most users prepare 100 mcg/0.1 mL or 1,000 mcg/mL
3. Use sterile bacteriostatic water (0.9% sodium chloride with benzyl alcohol preferred)
4. Draw calculated volume into sterile syringe
5. Slowly inject water into vial at an angle (avoid forceful injection, which causes foaming)
6. Let stand 2–3 minutes; do not shake
7. Gently roll between hands until fully dissolved (solution should be clear)
8. Aliquot into multiple insulin syringes (1 mL, 29–31 gauge) in sterile conditions
9. Store reconstituted peptide at 2–8°C; typical shelf-life 14–28 days depending on water type

Injection Protocol

1. Timing: Inject 30–60 minutes before food; morning preferred
2. Site Rotation: Alternate between abdomen (preferred), outer thigh, and love handles; maintain 1 inch spacing between injection sites
3. Preparation: Disinfect skin with alcohol pad; let dry completely
4. Technique: Pinch 1–2 inches of skin, insert needle at 45° angle, slowly depress plunger over 3–5 seconds
5. Post-Injection: Apply light pressure; do not massage injection site (may increase local irritation)
6. Frequency: Morning injection optimal; if dosing 2x daily, second dose mid-afternoon

Intranasal Protocol (if using this route)

1. Clear nasal passages gently
2. Insert nozzle into nostril, tilt head slightly forward
3. Depress spray button firmly; breathe gently through nose
4. Repeat in opposite nostril if full dose requires dual application
5. Remain upright for 2–3 minutes post-application

Cycle Example: 16-Week Metabolic Health Cycle

Off-Cycle Management: Maintain baseline nutrition, sleep, and exercise. Humanin levels will decline to pre-supplementation baseline within 2–3 weeks of cessation.

What to Expect: Timeline of Effects

Week 1–2: Initiation

• Most noticeable: Mild injection site reactions (redness, slight swelling) if subcutaneous; transient nasal irritation if intranasal
• Some users report mild fatigue or lethargy (dose-dependent)
• Blood glucose may fluctuate unpredictably; monitor fasting glucose closely if insulin-sensitive
• No obvious systemic effects

Week 3–4: Adaptation

• Injection site irritation typically resolves
• Subjective energy may improve or remain neutral
• Fasting glucose stabilization in insulin-resistant individuals
• Baseline inflammatory markers may transiently elevate (cytokine release)

Week 5–8: Primary Effect Window

• Improved insulin sensitivity becomes measurable (fasting insulin ↓, HOMA-IR improves)
• Sustained energy increase (if present) becomes consistent
• Fat loss acceleration may begin, particularly visceral fat
• Cognitive users report subjective clarity
• Injury recovery users note pain reduction

Week 9–12: Plateau & Optimization

• Effects stabilize; further improvements plateau unless dose escalated
• Body composition changes measurable on scale, DEXA, or imaging
• Inflammatory markers decline (if anti-inflammatory stack)
• Continued consistency in energy/cognitive benefits

Week 13–16: Late-Cycle Assessment

• Assess whether continuation justifies cost and injection burden
• Consider dose escalation if plateau achieved and no adverse effects
• Final biomarker collection pre-off-cycle

Week 17+: Off-Cycle

• Humanin levels return to baseline within 2–3 weeks
• Gains in insulin sensitivity and body composition stabilize if lifestyle maintained
• Cognitive/energy benefits fade over 3–4 weeks
• Slight rebound in inflammatory markers possible

Common Protocol Mistakes

1. Inconsistent Injection Timing

• Error: Varying injection times daily (morning one day, evening another)
• Impact: Inconsistent blood levels; reduced efficacy; unpredictable blood glucose fluctuations
• Fix: Set phone reminder for same time daily; prepare injection setup the night before

2. Over-Rotating Injection Sites

• Error: Using too many sites (more than 6 sites total) or re-injecting identical spots weekly
• Impact: Lipohypertrophy, reduced absorption, tissue damage
• Fix: Maintain systematic 4–6 site rotation (abdomen left/right, thigh left/right, love handles left/right); use each site no more than 2x per month

3. Premature Dose Escalation

• Error: Increasing from 200 mcg to 400+ mcg within 2 weeks
• Impact: Exaggerated hypoglycemic episodes, fatigue, potential receptor desensitization
• Fix: Escalate 50–100 mcg per 2-week block; allow 4+ weeks at each dose before increasing

4. Inadequate Reconstitution

• Error: Using non-sterile water, shaking vial vigorously, or preparing excessive volume
• Impact: Peptide degradation, bacterial contamination, shelf-life reduction to 3–5 days
• Fix: Use pharmaceutical-grade bacteriostatic water; gently roll vial; prepare 2-week supplies maximum; store at 2–8°C

5. Ignoring Hypoglycemic Warning Signs

• Error: Not monitoring fasting glucose; ignoring shakiness, sweating, or cognitive fog
• Impact: Severe hypoglycemia risk, especially if combining with insulin or GLP-1 agonists
• Fix: Check fasting glucose weekly during weeks 1–6; reduce humanin dose if fasting glucose drops below 70 mg/dL consistently

6. Stacking Humanin with Excessive Other Peptides

• Error: Adding TB-500, BPC-157, and multiple growth factors simultaneously
• Impact: Unpredictable interactions, inability to isolate which compound caused effects/side effects, receptor saturation
• Fix: Stack maximum 1–2 complementary peptides; wait 4–6 weeks between adding new compounds

7. Stopping Abruptly Mid-Cycle

• Error: Discontinuing without planned off-cycle taper
• Impact: Rapid loss of gains (especially metabolic); potential rebound inflammation
• Fix: Complete full cycle duration; allow structured 4–8 week off-cycle; do not stop and restart within same 4-week window

8. Neglecting Baseline & Monitoring Biomarkers

• Error: Starting humanin without fasting glucose, insulin, lipids, or inflammatory markers
• Impact: Cannot assess efficacy objectively; miss warning signs of metabolic dysregulation
• Fix: Draw baseline bloodwork before cycle; repeat at week 6, week 12, and end of cycle

How to Stack with Other Compounds

Synergistic Stacks

Stack A: Metabolic Optimization

• Humanin: 250 mcg daily
• GLP-1 Agonist (semaglutide 0.5–1.0 mg/week): Synergistic insulin sensitivity and body composition
• NAD+ Booster (NMN 500 mg daily): Amplifies mitochondrial effects
• Timing: Humanin morning; GLP-1 weekly; NMN morning with food
• Cycle: 14 weeks on; 6 weeks off (all simultaneously)

Stack B: Injury Recovery + Neuroprotection

• Humanin: 300 mcg daily
• BPC-157: 250 mcg daily (separate injection or nasal)
• Epithalon: 10 mg daily (teleomerase support)
• Timing: All morning; stagger injections by 10 minutes
• Cycle: 12 weeks on; 4 weeks off

Stack C: Athletic Performance + Mitochondrial

• Humanin: 300 mcg daily
• TB-500: 2 mg weekly (tissue repair)
• Exenatide (GLP-1): 5 mcg daily (metabolic, energy)
• Timing: Humanin morning; TB-500 Monday; Exenatide evening
• Cycle: 16 weeks on; 8 weeks off

Stack D: Anti-Aging + Longevity

• Humanin: 250 mcg daily
• Senolytics (Fisetin 100 mg or Dasatinib + Quercetin): 2x weekly (senescent cell clearance)
• CoQ10: 300 mg daily
• NAC: 1200 mg daily (antioxidant support)
• Cycle: 16 weeks on; 8 weeks off

Stack E: Cognitive Enhancement

• Humanin: 300 mcg daily
• Alpha-GPC: 600 mg daily (cholinergic support)
• Lion's Mane: